Lufaxin, a novel factor Xa inhibitor from the salivary gland of the sand fly lutzomyia longipalpis blocks protease-activated receptor 2 activation and inhibits inflammation and thrombosis in vivo

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 9, 2012, Pages 2185-2196

  Collin, Nicolas ^a,b   Assumpção, Teresa C F ^c   Mizurini, Daniella M ^d   Gilmore, Dana C ^a   Dutra Oliveira, Angélica ^d   Kotsyfakis, Michalis ^e   Sá Nunes, Anderson ^f   Teixeira, Clarissa ^a   Ribeiro, José M C ^c   Monteiro, Robson Q ^d   Valenzuela, Jesus G ^a   Francischetti, Ivo M B ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e INSTITUTE OF PARASITOLOGY   (Czech Republic)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

hematophagy; leishmaniasis; microcirculation; thrombosis; vector biology

Indexed keywords

ANTIINFLAMMATORY AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; FERROUS CHLORIDE; LUFAXIN; PROTEINASE ACTIVATED RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; CAROTID ARTERY THROMBOSIS; CELL LINE; EDEMA; ENZYME INHIBITION; EQUILIBRIUM CONSTANT; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; ISOTHERMAL TITRATION CALORIMETRY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHODIDAE; RAT; SALIVARY GLAND; STOICHIOMETRY; SURFACE PLASMON RESONANCE; THROMBOSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD COAGULATION; CALORIMETRY; CELL LINE, TUMOR; CHLORIDES; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FEMALE; FERRIC COMPOUNDS; FIBRINOLYTIC AGENTS; HEK293 CELLS; HUMANS; INFLAMMATION; INSECT PROTEINS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; PROTEIN BINDING; PROTHROMBIN TIME; PSYCHODIDAE; RATS; RECEPTOR, PAR-2; RECOMBINANT PROTEINS; SALIVARY GLANDS; SURFACE PLASMON RESONANCE; THROMBOPLASTIN; THROMBOSIS; TIME FACTORS;

EID: 84865510723     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.253906     Document Type: Article

References (50)

1. Ribeiro JM, Francischetti IM. Role of arthropod saliva in blood feeding: sialome and post-sialome perspectives. Annu Rev Entomol. 2003;48:73-88.
2. Koh CY, Kini RM. Molecular diversity of anticoagulants from haematophagous animals. Thromb Haemost. 2009;102:437-453.
3. Francischetti IM. Platelet aggregation inhibitors from hematophagous animals. Toxicon. 2010;56:1130-1144.
4. Takac P, Tsujimoto H, Champagne DE. Hypotensive proteins from hematophagous animals. In: Kini RM, Clemetson KJ, Markland FS, McLane MA, Morita T, eds. Toxins and Hemostasis: From Bench to Bedside. New York, NY: Springer; 2010:673-696.
5. Titus RG, Bishop JV, Mejia JS. The immunomodulatory factors of arthropod saliva and the potential for these factors to serve as vaccine targets to prevent pathogen transmission. Parasite Immunol. 2006;28:131-141.
6. Valenzuela JG, Belkaid Y, Rowton E, Ribeiro JM. The salivary apyrase of the blood-sucking sand fly Phlebotomus papatasi belongs to the novel Cimex family of apyrases. J Exp Biol. 2001;204(Pt 2):229-237.
7. Lerner EA, Ribeiro JM, Nelson RJ, Lerner MR. Isolation of maxadilan, a potent vasodilatory peptide from the salivary glands of the sand fly Lutzomyia longipalpis. J Biol Chem. 1991;266:11234-11236.
8. Valenzuela JG, Belkaid Y, Garfield MK, Mendez S, Kamhawi S, Rowton ED, Sacks DL, Ribeiro JM. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med. 2001;194:331-342.
9. Charlab R, Valenzuela JG, Rowton ED, Ribeiro JM. Toward an understanding of the biochemical and pharmacological complexity of the saliva of a hematophagous sand fly Lutzomyia longipalpis. Proc Natl Acad Sci USA. 1999;96:15155-15160.
10. Hostomská J, Volfová V, Mu J, Garfield M, Rohousová I, Volf P, Valenzuela JG, Jochim RC. Analysis of salivary transcripts and antigens of the sand fly Phlebotomus arabicus. BMC Genomics. 2009;10:282.
11. Anderson JM, Oliveira F, Kamhawi S, Mans BJ, Reynoso D, Seitz AE, Lawyer P, Garfield M, Pham M, Valenzuela JG. Comparative salivary gland transcriptomics of sandfly vectors of visceral leishmaniasis. BMC Genomics. 2006;7:52.
12. Krishnaswamy S. Exosite-driven substrate specificity and function in coagulation. J Thromb Haemost. 2005;3:54-67.
13. Rothmeier AS, Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol. 2012;34:133-149.
14. Rattenholl A, Steinhoff M. Proteinase-activated receptor-2 in the skin: receptor expression, activation and function during health and disease. Drug News Perspect. 2008;21:369-381.
15. Cottrell GS, Amadesi S, Schmidlin F, Bunnett N. Protease-activated receptor 2: activation, signalling and function. Biochem Soc Trans. 2003;31(Pt 6):1191-1197.
16. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3:1800-1814.
17. Broze GJ Jr, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci. 2012;17:262-280.
18. Olson ST, Gettins PG. Regulation of proteases by protein inhibitors of the serpin superfamily. Prog Mol Biol Transl Sci. 2011;99:185-240.
19. Rezaie AR. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma. Thromb Res. 2007;119:481-488.
20. Broze GJ Jr. Protein Z-dependent regulation of coagulation. Thromb Haemost. 2001;86:8-13.
21. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science. 1990;248:593-596.
22. Tsujimoto H, Kotsyfakis M, Francischetti IM, Eum JH, Strand MR, Champagne DE. Simukunin from the salivary glands of the black fly Simulium vittatum inhibits enzymes that regulate clotting and inflammatory responses. PLoS ONE. 2012;7:e29964.
23. Cappello M, Vlasuk GP, Bergum PW, Huang S, Hotez PJ. Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa. Proc Natl Acad Sci USA. 1995;92:6152-6156.
24. Dunwiddie C, Thornberry NA, Bull HG, Sardana M, Friedman PA, Jacobs JW, Simpson E. Antistasin, a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site. J Biol Chem. 1989;264:16694-16699.
25. Stark KR, James AA. Isolation and characterization of the gene encoding a novel factor Xa-directed anticoagulant from the yellow fever mosquito, Aedes aegypti. J Biol Chem. 1998;273:20802-20809.
26. Narasimhan S, Koski RA, Beaulieu B, Anderson JF, Ramamoorthi N, Kantor F, Cappello M, Fikrig E. A novel family of anticoagulants from the saliva of Ixodes scapularis. Insect Mol Biol. 2002;11:641-650.
27. Oliveira F, Kamhawi S, Seitz AE, Pham VM, Guigal PM, Fischer L, Ward J, Valenzuela JG. From transcriptome to immunome: identification of DTH inducing proteins from a Phlebotomus ariasi salivary gland cDNA library. Vaccine. 2006;24:374-390.
28. Ma D, Assumpção TC, Li Y, Andersen JF, Ribeiro J, Francischetti IM. Triplatin, a platelet aggregation inhibitor from the salivary gland of the triatomine vector of Chagas disease, binds to TXA(2) but does not interact with glycoprotein PVI. Thromb Haemost. 2012;107:111-123.
29. Assumpção TC, Alvarenga PH, Ribeiro JM, Andersen JF, Francischetti IM. Dipetalodipin, a novel multifunctional salivary lipocalin that inhibits platelet aggregation, vasoconstriction, and angiogenesis through unique binding specificity for TXA2, PGF2alpha, and 15(S)-HETE. J Biol Chem. 2010;285:39001-39012.
30. Monteiro RQ, Rezaie AR, Ribeiro JM, Francischetti IM. Ixolaris: a factor Xa heparin-binding exosite inhibitor. Biochem J. 2005;387(Pt 3):871-877.
31. Francischetti IM, Valenzuela JG, Ribeiro JM. Anophelin: kinetics and mechanism of thrombin inhibition. Biochemistry. 1999;38:16678-16685.
32. Camerer E, Huang W, Coughlin SR. Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA. 2000;97:5255-5260.
33. Kotsyfakis M, Sá-Nunes A, Francischetti IM, Mather TN, Andersen JF, Ribeiro JM. Antiinflammatory and immunosuppressive activity of sialostatin L, a salivary cystatin from the tick Ixodes scapularis. J Biol Chem. 2006;281:26298-26307.
34. Williams JW, Morrison JF. The kinetics of reversible tight-binding inhibition. Meth Enzymol. 1979;63:437-467.
35. Copeland RA. Tight binding inhibitors. In: Copeland RA, ed. Enzymes: A Practical Introduction to Strucuture, Mechanism, and Data Analysis. New York, NY: Wiley-VCH Inc; 2000:305-317.
36. Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res. 2006;66:307-314.
37. Rydén L, Grabau D, Schaffner F, Jönsson PE, Ruf W, Belting M. Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int J Cancer. 2010;126:2330-2340.
38. Cirino G, Cicala C, Bucci M, Sorrentino L, Ambrosini G, DeDominicis G, Altieri DC. Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest. 1997;99:2446-2451.
39. Owens AP 3rd, Lu Y, Whinna HC, Gachet C, Fay WP, Mackman N. Towards a standardization of the murine ferric chloride-induced carotid arterial thrombosis model. J Thromb Haemost. 2011;9:1862-1863.
40. Wei A, Alexander RS, Duke J, Ross H, Rosenfeld SA, Chang CH. Unexpected binding mode of tick anticoagulant peptide complexed to bovine factor Xa. J Mol Biol. 1998;283:147-154.
41. Rios-Steiner JL, Murakami MT, Tulinsky A, Arni RK. Active and exo-site inhibition of human factor Xa: structure of des-Gla factor Xa inhibited by NAP5, a potent nematode anticoagulant protein from Ancylostoma caninum. J Mol Biol. 2007;371:774-786.
42. Lapatto R, Krengel U, Schreuder HA, Arkema A, de Boer B, Kalk KH, Hol WG, Grootenhuis PD, Mulders JW, Dijkema R, Theunissen HJ, Dijkstra BW. X-ray structure of antistasin at 1.9 A resolution and its modelled complex with blood coagulation factor Xa. EMBO J. 1997;16:5151-5161.
43. Otlewski J, Jelen F, Zakrzewska M, Oleksy A. The many faces of protease-protein inhibitor interaction. EMBO J. 2005;24:1303-1310.
44. Zögg T, Brandstetter H. Complex assemblies of factors IX and X regulate the initiation, maintenance, and shutdown of blood coagulation. Prog Mol Biol Transl Sci. 2011;99:51-103.
45. Leavitt S, Freire E. Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr Opin Struct Biol. 2001;11:560-566.
46. Lindner JR, Kahn ML, Coughlin SR, Sambrano GR, Schauble E, Bernstein D, Foy D, Hafezi-Moghadam A, Ley K. Delayed onset of inflammation in protease-activated receptor-2-deficient mice. J Immunol. 2000;165:6504-6510.
47. Lohman RJ, Cotterell AJ, Suen J, Liu L, Do AT, Vesey DA, Fairlie DP. Antagonism of protease-activated receptor 2 protects against experimental colitis. J Pharmacol Exp Ther. 2012;340:256-265.
48. Sevigny LM, Zhang P, Bohm A, Lazarides K, Perides G, Covic L, Kuliopulos A. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci USA. 2011;108:8491-8496.
49. Moormann C, Artuc M, Pohl E, Varga G, Buddenkotte J, Vergnolle N, Brehler R, Henz BM, Schneider SW, Luger TA, Steinhoff M. Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. J Invest Dermatol. 2006;126:746-755.
50. Borensztajn K, Spek CA. Blood coagulation factor Xa as an emerging drug target. Expert Opin Ther Targets. 2011;15:341-349.